Galleri Test Alternatives: Multi-Cancer Blood Tests | YEARS
A single blood test to detect over 50 types of cancer, years before symptoms appear—that is the promise of the Galleri test. While the name frequently appears in the media, the test remains far from…
A single blood test to detect over 50 types of cancer, years before symptoms appear—that is the promise of the Galleri test. While the name frequently appears in the media, the test remains far from established standard care, particularly in Europe and Germany. For many patients, it raises more questions than it answers.
What valid Galleri test alternatives are available? How do they compare, what do they cost, and for whom do they make sense?
This article provides an evidence-based assessment. We analyze the technology behind these tests, compare available options, and outline a strategy that goes beyond a single laboratory value: prevention based on a complete health picture.
What is the Galleri Test and How Does It Work?
The Galleri test is a so-called liquid biopsy. It analyzes cell-free DNA (cfDNA)—small DNA fragments released into the blood by all cells in your body. When tumor cells die, they also release their genetic information, which then becomes detectable in the blood as circulating tumor DNA (ctDNA).
The Technology: Methylation Patterns in Liquid Biopsy
The innovation of the Galleri test, developed by the company GRAIL, lies in the analysis of specific biochemical markers on this DNA: the so-called methylation patterns.
Cancer cells often exhibit abnormal methylation patterns, comparable to characteristic "typos" on the DNA that do not occur in healthy tissue. Galleri uses machine learning to identify these cancer-specific patterns in the blood. The test can thereby make a prediction about which organ the tumor might have originated in (Cancer Signal Origin).
Sensitivity vs. Specificity: The Limits of Accuracy
To evaluate the performance of such tests, two metrics are crucial:
- Specificity: How well does the test correctly identify healthy individuals as healthy? High specificity minimizes the number of false-positive results. According to studies, Galleri achieves over 99.5% here: Out of 1,000 healthy individuals, fewer than five receive a falsely positive result.
- Sensitivity: How reliably does the test actually detect an existing cancer? The overall sensitivity of Galleri across all cancer types and stages is approximately 51.5%. The test thus detects about half of all cancers in the studied population.
However, sensitivity increases significantly as the disease progresses:
- Stage I (early stage): 16.8%
- Stage II: 40.4%
- Stage III: 77.0%
- Stage IV (advanced): 90.1%
The more advanced the tumor, the more reliable the detection. Especially in the early stages, where detection would have the greatest clinical benefit, the detection rate remains limited.
Is the Galleri Test Available in Europe and Germany?
Despite its prominence, the Galleri test is not an established screening procedure in the German or broader European healthcare system.
Regulatory Reality and the NHS Trial
For widespread application, a medical device must be evaluated in a way that allows it to be recommended for population-wide screening. For Galleri, this is not yet the case in Europe. The process is also still ongoing in the US; GRAIL reported the final submission for FDA review in January 2026.
The largest study to date on the Galleri test, conducted by the UK's National Health Service (NHS) with over 140,000 participants, showed a nuanced picture: The primary endpoint, a significant reduction in late-stage cancers, was not met. However, the increased detection rate compared to standard care was measurable. Experts therefore view the result as a promising step, not as conclusive proof.
Costs and Private Use: What Self-Payers Need to Know
Individual private physicians and specialized clinics in Germany offer the Galleri test as an individual health service (IGeL). You bear the costs entirely yourself. They range between €800 and €1,200.
Even for privately insured individuals (PKV), cost coverage is not guaranteed. Purely preventive measures without a specific suspicion of illness are rarely reimbursed.
Galleri Test Alternatives: A Systematic Comparison
The limited availability of Galleri has created space for other technologies and tests in Germany. Here is an overview of the most important options.
| Test / Method | Technology | Focus | Availability in DE | Approximate Costs (isolated) |
|---|---|---|---|---|
| Galleri | Analysis of methylation patterns (cfDNA) | Multi-Cancer (50+ cancer types) | Very limited (Self-pay) | €800 – €1,200 |
| truCheck (YEARS) | Analysis of circulating tumor cells (CTCs) | Multi-Cancer (70+ solid tumors) | Available (in programs) | Part of [YEARS Evolve®](/years-evolve) (€7,600) |
| PanTum Detect | EDIM technology (Apo10 & TKTL1 markers) | Multi-Cancer (non-specific) | Available (Self-pay) | €500 – €700 |
| Shield Test | Analysis of methylation patterns (cfDNA) | Colon cancer only | Not available | N/A |
| Standard Screening | Colonoscopy, Mammo, Pap, etc. | Specific cancer types | Widespread (Public/Private Insurance) | Covered by insurance |
PanTum Detect (EDIM Technology)
This test is based on EDIM technology and measures biomarkers on immune cells. The German Cancer Society currently does not recommend EDIM-based tests for early cancer detection, as the diagnostic value for screening healthy individuals is considered insufficiently proven.
truCheck at YEARS (Analysis of Circulating Tumor Cells)
The Berlin-based prevention clinic YEARS integrates the truCheck blood test into its Evolve® and Ultimate® programs. This test analyzes whole circulating tumor cells (CTCs) instead of just their DNA fragments and may potentially provide indications of over 70 solid tumor types. The crucial difference compared to ordering an isolated test online: At YEARS, the liquid biopsy is part of a comprehensive diagnostic day, medically supervised, and interpreted in the context of all other findings.
A Critical Assessment: What You Should Consider When Choosing
No blood test replaces established standard screening. Examinations such as colonoscopy (colon cancer), mammography (breast cancer), or Pap smears (cervical cancer) remain the gold standard for their respective indications. Multi-Cancer Early Detection (MCED) tests are intended as a complement, not a replacement.
The Problem with Isolated Tests: The Cost of False Positives
Even with a high specificity of 99.5%, 5 out of 1,000 healthy people will receive a false alarm. This almost always leads to anxiety, stress, and a cascade of further examinations: PET-CT, MRI, biopsies. This costs time, money, and places a significant burden on those affected and their families.
A patient who receives a positive result by mail without medical context is left with an outcome they cannot interpret. Medical consultation before the test and professional guidance afterward are therefore not optional extras, but a medical necessity.
The Better Strategy: Integrated Diagnostics Instead of Single Data Points
A single blood test provides you with one layer of data. A robust prevention strategy requires multiple, intelligently linked layers.
Step 1: The Foundation – Your Medical Baseline (YEARS Core®)
Before considering highly specialized tests, you need a solid baseline. The YEARS Core® Program establishes this in a single day:
- 87+ Biomarkers: Going far beyond the standard, including ApoB, hs-CRP, and HOMA index, which provide crucial indications of cardiovascular and metabolic risks.
- Imaging: Advanced ultrasound of the heart, abdominal organs, thyroid, and blood vessels.
- Functional Diagnostics: Measurement of your lung function (body plethysmography) and your cardiorespiratory fitness (VO₂max), one of the strongest single predictors of longevity.
- AI Screenings: Skin cancer screening (ATBM Master) and retinal analysis (AI funduscopy).
With this foundation, you have a comprehensive, medically contextualized basis for all further decisions.
Step 2: The Addition – Molecular and Structural Diagnostics (YEARS Evolve®)
Advanced diagnostics can be sensibly built upon this foundation. The YEARS Evolve® Program combines the truCheck blood test (liquid biopsy) with a whole-body MRI:
- The blood test looks for molecular traces that may potentially indicate cancer.
- The MRI can simultaneously visualize a structural map of your entire body.
This combination is vastly more powerful than an isolated test because signals from the blood can be correlated with structural findings.
Step 3: The Apex – Genomics and Personalized Prevention (YEARS Ultimate®)
The YEARS Ultimate® Program adds further layers, including whole-exome and whole-genome sequencing to analyze hundreds of cancer-relevant genes, as well as a microbiome analysis of the gut flora.
Your Roadmap: From Data to a Clear Strategy
Blood tests for early cancer detection are tools with potential, but the research is not yet conclusive. For a robust, actionable prevention strategy, we recommend a step-by-step approach:
- Build a foundation: Start with a comprehensive, medically guided baseline assessment that goes far beyond a standard blood panel. The YEARS Core® Program provides you with this multidimensional baseline.
- Integrate instead of isolate: For deeper early detection, choose an approach that combines liquid biopsy with whole-body MRI, as in the YEARS Evolve® Program.
- Get medical guidance: Data without interpretation is useless. An experienced medical team that translates your results into a prioritized action plan is the crucial part of the process.
A single blood test gives you a data point. An integrated diagnostic program gives you a strategy.
If you are ready to take a proactive step toward preventive health, schedule a non-binding consultation now.
---
This article does not replace individual medical advice.
---
Sources
- GRAIL, LLC. (2021). The PATHFINDER Study: A Prospective Study of a Test for Multi-Cancer Early Detection. ClinicalTrials.gov Identifier: NCT04241796.
- GRAIL, LLC. (2024). NHS-Galleri trial primary endpoint analysis and top-line results presented at 2024 ASCO Annual Meeting. Pressemitteilung.
- GRAIL, LLC. (2026). GRAIL submits FDA Premarket Approval application for the Galleri multi-cancer early detection test. Pressemitteilung.
- HanseMerkur Versicherungsgruppe. (2024). Krebs-Scan: Die innovative Krebsvorsorge. Produktseite.
- Klein, E. A., et al. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167-1177. DOI: 10.1016/j.annonc.2021.05.806.
- U.S. Food and Drug Administration (FDA). (2024). SHIELD Blood Test Approval. Pressemitteilung.
Related reading: Ezra vs. Prenuvo vs. YEARS: A Full-Body Scan Comparison | Full Body MRI vs CT Scan: Radiation, Accuracy & Costs | Liquid Biopsy for Cancer: Promise vs. Reality | Liquid biopsy at YEARS
Frequently asked questions on this topic
Does private health insurance cover blood tests for early cancer detection?
Most German private health insurance plans do not reimburse an isolated test as a self-pay service, because a pure screening examination without concrete suspicion of disease is rarely deemed medically necessary. The YEARS programs are billed according to the German medical fee schedule (GOÄ). That gives you an invoice with individually itemised entries rather than a flat program fee, which is the precondition for submitting anything at all. Whether individual entries are reimbursed is decided solely by your insurer, based on tariff, indication and case review. Nobody can promise you an outcome in advance. Clarify the scope with your tariff before booking, ideally with an itemised list of services rather than the program name.
How long does it take to get the results?
A liquid biopsy result alone is usually available after one to two weeks. At YEARS the process is integrated: about two weeks after your diagnostic day you receive your 60-plus page Health Report and discuss all findings, meaning blood test, MRI and biomarkers, in a detailed strategy session with the medical team. That bundling is deliberate. A cancer signal in the blood only becomes meaningful once it is weighed against imaging, conventional tumour markers and your family history. If a finding emerges that cannot wait until the consultation, we contact you immediately rather than sticking to the regular schedule. Until the consultation you will not receive raw findings by email, because individual values without interpretation unsettle more than they help.
What does a positive result mean?
A positive result is not a cancer diagnosis. It is a risk signal that requires further, targeted diagnostic steps. This is where the advantage of an integrated program becomes apparent: the medical team already has extensive additional data available, such as from the MRI, which helps contextualise the signal before invasive examinations need to be ordered. Because modern methods also indicate the likely tissue of origin, investigation can be planned in a targeted way rather than searching the whole body. Honesty requires adding this: a proportion of positive signals are not confirmed on investigation, and the waiting period is a burden. We explain exactly that before the test, not after.
